Mounjaro vs Ozempic: which works better, and what it costs you
These are two popular prescription weight-loss and diabetes drugs that people often compare to each other. This guide compares how well each works, their side effects, and what they actually cost.
For weight loss, tirzepatide (Mounjaro, Zepbound) outperforms semaglutide (Ozempic, Wegovy) across every direct comparison published so far — but the evidence is weaker than the headlines imply, and the difference matters less than whether you can tolerate the drug, afford it long term, and stay on it.
- Tirzepatide acts on two hormone receptors (GIP and GLP-1); semaglutide acts on one. That mechanistic difference is the likely reason for the efficacy gap.
- A 2025 meta-analysis of 28,980 people found greater weight loss with tirzepatide — but only two of its seven studies were randomised, and heterogeneity was extreme (I² above 90%).
- The most-quoted head-to-head figures come from an indirect comparison authored by Eli Lilly employees, who make tirzepatide. That does not make it wrong; it does mean it is not independent.
- Side-effect profiles are broadly similar: mostly gastrointestinal, mostly early, mostly dose-dependent.
- Both regain weight after stopping. Neither is a course of treatment; both are ongoing therapy.
The same two molecules, four brand names
What is actually being compared
| Brand | Molecule | Approved for | Acts on |
|---|---|---|---|
| Mounjaro | Tirzepatide | Type 2 diabetes | GIP + GLP-1 receptors |
| Zepbound | Tirzepatide | Weight management | GIP + GLP-1 receptors |
| Ozempic | Semaglutide | Type 2 diabetes | GLP-1 receptor |
| Wegovy | Semaglutide | Weight management | GLP-1 receptor |
Tirzepatide is a dual agonist: it activates the GIP receptor as well as the GLP-1 receptor. Semaglutide activates GLP-1 alone. That extra mechanism is the most plausible explanation for the efficacy difference seen in the data, and it is also why the two drugs are not interchangeable in the way two statins might be.
What the head-to-head evidence actually shows
Two pieces of evidence carry most of the weight here, and both point the same direction — with caveats that are rarely reported alongside them.
The direct comparisons
| Study | Design | Population | Finding |
|---|---|---|---|
| Cureus, 2025 | Meta-analysis of 7 direct-comparison studies (2 randomised, 5 observational) | 28,980 adults with overweight or obesity | Tirzepatide superior; ~1.33% greater weight reduction at 6 months |
| Diabetes Obes Metab, 2025 | Indirect comparison of SURMOUNT-2 and STEP 2 | Adults with obesity and type 2 diabetes | Tirzepatide 15 mg: 4.79% greater weight reduction than semaglutide 2.4 mg |
What that adds up to
- Direction: tirzepatide produces more weight loss than semaglutide. This is consistent across every comparison published.
- Magnitude: somewhere between roughly 1% and 5% additional body weight, depending on dose, duration and which analysis you trust.
- Certainty: moderate at best. There is still no large, independent, randomised head-to-head trial designed specifically to answer this question.
Side effects: more similar than different
Both drugs share a side-effect profile driven by the same mechanism — slowed gastric emptying and appetite suppression. Most effects appear during dose escalation and settle; the ones that matter clinically are rarer and worth knowing by name.
Reported effects, both molecules
| Effect | Frequency | What to do |
|---|---|---|
| Nausea, vomiting | Common, especially when escalating dose | Usually settles; slower titration helps |
| Diarrhoea or constipation | Common | Manageable; tell your prescriber if persistent |
| Reduced appetite, early fullness | Expected — it is the mechanism | Prioritise protein to limit muscle loss |
| Gallbladder problems | Uncommon | Seek care for severe right-sided abdominal pain |
| Pancreatitis | Rare | Severe persistent abdominal pain is an emergency |
| Muscle loss alongside fat loss | Consistently observed | Resistance training and adequate protein |
Cost, coverage and the part people underestimate
Both are expensive without insurance, and coverage in the United States commonly depends on whether you are prescribed the diabetes brand or the weight-management brand. The larger financial question is not the monthly price but the duration: these are ongoing therapies, and stopping reliably reverses the result.
- Insurance is more likely to cover a diabetes indication than a weight indication, which is why prescription choice is often driven by coverage rather than pharmacology.
- Manufacturer savings programmes materially change out-of-pocket cost and are worth checking before assuming a price.
- Compounded versions sold online are not the same product, are not FDA-approved, and carry sourcing and dosing risks that the branded products do not.
- Budget for continuation, not a course. Trials consistently show substantial weight regain after discontinuation.
Which one fits which person
Ranked on: fit for a stated goal, given the current evidence — not a quality league table. Both are effective drugs, and the right answer is frequently decided by tolerability and coverage rather than by efficacy data.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | Maximum weight reduction is the priority | Tirzepatide | — |
| 2 | Cardiovascular risk reduction is the priority | Semaglutide | — |
| 3 | You have struggled with GI side effects before | Either, titrated slowly | — |
| 4 | Cost is the binding constraint | Whichever is covered | — |
- 01
Maximum weight reduction is the priority
TirzepatideEvery published direct comparison favours it, and the mechanistic rationale is coherent. If weight loss is the objective and cost and tolerability permit, this is what the evidence supports.
- 02
Cardiovascular risk reduction is the priority
SemaglutideSemaglutide has the longer track record and a larger body of published cardiovascular outcome data. Where the goal is risk reduction rather than the scale, that history carries weight.
- 03
You have struggled with GI side effects before
Either, titrated slowlyNeither molecule is reliably gentler. Slower escalation matters more than which drug you choose, and it is the single most useful thing to raise with your prescriber.
- 04
Cost is the binding constraint
Whichever is coveredA drug you can stay on for two years beats a marginally better one you stop after four months. Regain after discontinuation makes adherence the dominant variable.
Frequently asked questions
Is Mounjaro better than Ozempic for weight loss?
On the published evidence, yes — every direct comparison to date favours tirzepatide over semaglutide for weight reduction. The size of the advantage is uncertain: a 2025 meta-analysis of nearly 29,000 people found roughly 1.33% greater weight loss at six months, while an industry-authored indirect comparison put the gap at up to 4.79%. Both point the same way; neither is a large independent randomised head-to-head trial, which still does not exist.
Can I switch from Ozempic to Mounjaro?
Switching between GLP-1 medications is done in practice, but the dose does not transfer across — tirzepatide has its own escalation schedule and starting at an equivalent-sounding dose is not appropriate. This is a prescriber decision, not a self-managed one.
Do the side effects differ between them?
Not substantially. Both share a gastrointestinal profile driven by the same mechanism, both are dose-dependent, and both tend to ease after escalation. Individual tolerance varies more than the drugs do, which is why titration speed usually matters more than the choice of molecule.
What happens when you stop taking either one?
Weight is regained. Trials of both molecules show substantial regain after discontinuation, because the drugs suppress appetite while they are being taken and that effect ends when they do. Treat them as ongoing therapy rather than a course, and plan the financial and clinical commitment accordingly.
Are compounded versions the same thing?
No. Compounded semaglutide and tirzepatide are not FDA-approved products, may use different salt forms, and carry sourcing, sterility and dosing risks the branded products do not. The price difference reflects a real difference in oversight.
Keep reading
- NMN: what the human trials actually show
A worked example of how we grade evidence, including where trials disagree.
- How we grade evidence
Why biomarkers alone never reach our top grade.
- Free stack check
Screen a GLP-1 against everything else you take before you start.
More in Therapies
- Weight-loss peptides compared: semaglutide, tirzepatide, retatrutide and CagriSema ranked by evidence
Semaglutide, tirzepatide, retatrutide and CagriSema ranked by real trial data — including which ones are actually approved and which are still years away.